Beamtree Holdings Ltd (AU:BMT)
ASX:BMT
Want to see AU:BMT full AI Analyst Report?
BMT Stock Chart & Stats
AU$0.22
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.22
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.33
Previous CloseN/A
Volume9.49K
Average Volume (3M)122.51K
Market Cap
AU$27.62M
Enterprise ValueAU$28.61M
Total Cash (Recent Filing)AU$2.94M
Total Debt (Recent Filing)AU$3.65M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding290,696,170
10 Day Avg. Volume152,204
30 Day Avg. Volume122,509
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)1.72
Price to Sales (P/S)2.53
P/FCF Ratio-39.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$29.88M
Bulls Say, Bears Say
Bulls Say
Durable Market Need For Clinical Decision SupportBeamtree’s core products target hospitals' ongoing need to digitalise acute-care workflows and improve clinical documentation. This alignment with sustained hospital digitisation and quality-improvement mandates supports recurring licensing and implementation demand over multiple quarters, underpinning steady revenue channels.
Proprietary Structured Data And NLP CapabilitiesUse of structured clinical data combined with NLP creates product differentiation and measurable clinical/operational ROI. These technical capabilities drive tighter integration with hospital workflows, higher switching costs, and stronger renewal economics, supporting durable customer retention and competitive positioning.
Conservative Leverage On The Balance SheetA low debt-to-equity profile and stable equity ratio reduce solvency and refinancing risk, giving management flexibility to fund product development or endure operating losses. This conservative capital structure extends runway and supports multi-quarter execution of commercial initiatives without immediate liquidity stress.
Bears Say
Negative Profitability And Weak MarginsReported negative EBIT/EBITDA and net profit margins indicate ongoing unprofitable operations. Persistent losses erode equity and limit reinvestment capacity; over several quarters this constrains the ability to scale go-to-market and product efforts without external funding or meaningful cost restructuring.
Poor Cash Generation / Negative Free Cash FlowNegative free cash flow growth and weak operating cash conversion point to liquidity pressure. Continued cash deficits increase the likelihood of dilutive capital raises or constrained investment in sales and R&D, limiting the company’s ability to execute strategic initiatives over a multi‑quarter horizon.
Revenue Growth DeteriorationA turn to negative revenue growth signals weakening demand or competitive share loss. Declining top‑line reduces leverage on fixed costs, compresses margins further, and slows the path to sustainable profitability; reversing this trend will require sustained commercial traction or product-market wins across quarters.
Beamtree Holdings Ltd News
BMT FAQ
What was Beamtree Holdings Ltd’s price range in the past 12 months?
Beamtree Holdings Ltd lowest share price was AU$0.08 and its highest was AU$0.33 in the past 12 months.
What is Beamtree Holdings Ltd’s market cap?
Beamtree Holdings Ltd’s market cap is AU$27.62M.
When is Beamtree Holdings Ltd’s upcoming earnings report date?
Beamtree Holdings Ltd’s upcoming earnings report date is Aug 26, 2026 which is in 73 days.
How were Beamtree Holdings Ltd’s earnings last quarter?
Beamtree Holdings Ltd released its earnings results on Feb 18, 2026. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Beamtree Holdings Ltd overvalued?
According to Wall Street analysts Beamtree Holdings Ltd’s price is currently Overvalued.
Does Beamtree Holdings Ltd pay dividends?
Beamtree Holdings Ltd does not currently pay dividends.
What is Beamtree Holdings Ltd’s EPS estimate?
Beamtree Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beamtree Holdings Ltd have?
Beamtree Holdings Ltd has 290,696,170 shares outstanding.
What happened to Beamtree Holdings Ltd’s price movement after its last earnings report?
Beamtree Holdings Ltd reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Beamtree Holdings Ltd?
Currently, no hedge funds are holding shares in AU:BMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beamtree Holdings Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.00%
12-Months-Change
Fundamentals
Return on Equity
-14.19%
Trailing 12-Months
Asset Growth
-5.78%
Trailing 12-Months
Company Description
Beamtree Holdings Ltd
Headquartered in Redfern, Australia, Beamtree Holdings Limited, founded in 1996, develops and markets cutting-edge clinical decision support (CDS) solutions for the healthcare sector, both within Australia and globally. The company offers a diverse range of products aimed at improving operational accuracy and patient outcomes. Among these are RippleDown Expert, providing live patient monitoring and notification capabilities, and RippleDown Auditor, which automates real-time data verification to ensure precision in billing, data entry, and specimen reception while identifying potential errors. Beamtree also offers PICQ, a quality assessment tool for clinically coded data used by public and private hospitals, health services, and state health authorities, alongside RISQ, designed for the measurement, benchmarking, and management of hospital-acquired complications. Further expanding its suite, the Q Coding Platform delivers an end-to-end workflow for clinical coding, grouping, reporting, and auditing, supported by Codexpert, a digital reference application for classification information in patient records. Additionally, the company provides expert advisory and auditing services, such as desktop analysis, data maturity assessments, and physical audits, reaching its clientele through strategic channel partners. The company adopted its current name, Beamtree Holdings Limited, in August 2021, having previously been known as PKS Holdings Limited.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
―
Alcidion Group Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---